Skip to main content

Table 3 Fatty acid distribution of cellular lipids treated with different milk lipids at 8 h

From: Influence of in vitro supplementation with lipids from conventional and Alpine milk on fatty acid distribution and cell growth of HT-29 cells

  Control   MLcon MLalp
  0.25% EtOH   100 μM   200 μM   100 μM   200 μM  
FAME [%] Mean   SD   Mean   SD   Mean   SD   Mean   SD   Mean   SD  
C14:0 1.58 ± 0.39 d 6.38 ± 0.87 bc 7.96 ± 0.94 a 5.38 ± 0.57 c 6.81 ± 0.51 ab
C14:1 c 9 0.10 ± 0.04 d 0.24 ± 0.05 bc 0.33 ± 0.05 a 0.22 ± 0.05 c 0.30 ± 0.03 ab
C15:0 0.25 ± 0.03 d 1.02 ± 0.09 bc 1.18 ± 0.08 a 1.08 ± 0.09 c 1.28 ± 0.07 ab
C16:0 20.92 ± 0.95 d 34.53 ± 1.89 b 36.96 ± 1.35 a 26.52 ± 1.14 c 26.77 ± 0.99 c
C16:1 c 9 12.75 ± 0.74 a 8.11 ± 0.80 b 6.64 ± 0.52 c 7.11 ± 0.51 bc 5.58 ± 0.36 d
C16:2 t 7,c 9 -   -   -   0.03 ± 0.01 b 0.05 ± 0.01 a
C17:0 0.44 ± 0.03 c 0.64 ± 0.04 b 0.63 ± 0.02 b 0.69 ± 0.04 a 0.67 ± 0.02 ab
C18:0 13.02 ± 0.47 a 10.23 ± 0.29 b 9.34 ± 0.63 c 10.13 ± 0.37 b 8.66 ± 0.27 c
C18:1 c 9 34.32 ± 0.82 a 25.93 ± 1.71 c 25.02 ± 1.66 c 29.23 ± 1.32 b 29.05 ± 1.34 b
C18:1 c 11 3.25 ± 0.18 a 1.85 ± 0.24 b 1.47 ± 0.08 c 1.90 ± 0.12 b 1.56 ± 0.07 c
C18:1 c 12-15 -   0.31 ± 0.10 b 0.39 ± 0.09 ab 0.42 ± 0.13 ab 0.48 ± 0.11 a
C18:1 t 4-8 -   0.03 ± 0.01 bc 0.03 ± 0.01 bc 0.08 ± 0.06 ab 0.11 ± 0.05 a
C18:1 t 9 -   0.10 ± 0.03 b 0.10 ± 0.04 b 0.16 ± 0.04 ab 0.19 ± 0.07 a
C18:1 t 10 -   0.14 ± 0.04 b 0.18 ± 0.03 b 0.19 ± 0.04 b 0.25 ± 0.05 a
C18:1 t 11 (VA) -   0.27 ± 0.03 c 0.34 ± 0.03 c 2.50 ± 0.20 b 3.32 ± 0.16 a
C18:1 t 12-16 -   0.42 ± 0.14 c 0.54 ± 0.18 bc 0.75 ± 0.19 ab 0.92 ± 0.20 a
C18:2 n-6 2.65 ± 0.13 a 2.08 ± 0.05 cd 2.04 ± 0.17 d 2.28 ± 0.07 b 2.25 ± 0.11 bc
C18:2 n-6 (t,t) -   0.21 ± 0.06 d 0.29 ± 0.03 c 0.43 ± 0.04 b 0.54 ± 0.03 a
C18:2 c 9,t 11 0.09 ± 0.01 e 0.32 ± 0.01 d 0.37 ± 0.03 c 2.47 ± 0.07 b 3.18 ± 0.14 a
C18:2 t 11,c 13 -   -   -   0.18 ± 0.02 b 0.26 ± 0.02 a
C18:2 t 9,t 11 -   0.03 ± 0.01 cd 0.04 ± 0.01 c 0.18 ± 0.02 b 0.24 ± 0.03 a
C18:3 n-3 0.22 ± 0.03 d 0.33 ± 0.02 c 0.42 ± 0.05 c 0.96 ± 0.02 b 1.31 ± 0.09 a
C20:0 0.38 ± 0.03 a 0.30 ± 0.02 b 0.24 ± 0.03 c 0.28 ± 0.02 b 0.20 ± 0.02 c
C20:1 c 9 0.33 ± 0.07 a 0.17 ± 0.04 bc 0.15 ± 0.02 d 0.23 ± 0.04 b 0.18 ± 0.02 bc
C20:3 n-6 1.19 ± 0.14 a 0.63 ± 0.05 b 0.49 ± 0.04 cd 0.58 ± 0.06 bc 0.42 ± 0.05 d
C20:4 n-6 2.38 ± 0.25 a 1.20 ± 0.09 b 0.86 ± 0.05 c 1.13 ± 0.13 b 0.77 ± 0.09 c
C20:5 n-3 0.70 ± 0.05 a 0.35 ± 0.04 bc 0.27 ± 0.02 d 0.39 ± 0.03 b 0.31 ± 0.03 cd
C22:5 n-3 1.34 ± 0.15 a 0.70 ± 0.11 b 0.53 ± 0.06 c 0.69 ± 0.08 bc 0.54 ± 0.07 bc
C22:6 n-3 1.76 ± 0.16 a 0.82 ± 0.11 b 0.58 ± 0.05 c 0.78 ± 0.10 b 0.53 ± 0.07 c
∑ SFA 38.65 ± 0.88 a 55.47 ± 2.59 b 58.67 ± 1.83 a 46.78 ± 1.59 c 47.29 ± 1.66 c
∑ MUFA 50.84 ± 0.34 b 37.69 ± 2.28 c 35.30 ± 1.49 c 42.91 ± 1.34 b 42.07 ± 1.22 b
∑ PUFA incl. CLA 10.51 ± 0.86 a 6.84 ± 0.47 b 6.03 ± 0.44 b 10.31 ± 0.44 a 10.64 ± 0.56 a
∑ PUFA n-3 4.14 ± 0.36 a 2.31 ± 0.28 c 1.88 ± 0.16 c 2.95 ± 0.21 b 2.82 ± 0.22 b
∑ PUFA n-6 6.28 ± 0.51 a 3.98 ± 0.18 bc 3.46 ± 0.25 d 4.07 ± 0.25 b 3.54 ± 0.23 cd
PUFA/SFA 0.27 ± 0.03 a 0.12 ± 0.01 c 0.10 ± 0.01 c 0.22 ± 0.02 b 0.23 ± 0.02 b
n-6/n-3 1.52 ± 0.06 b 1.74 ± 0.17 a 1.85 ± 0.07 a 1.38 ± 0.03 bc 1.26 ± 0.02 c
∑ SFA + t FA 38.65 ± 0.88 d 56.71 ± 2.73 b 60.23 ± 2.06 a 50.97 ± 2.04 c 52.73 ± 1.91 c
∑ C18:1 (t) -   0.96 ± 0.18 c 1.18 ± 0.26 c 3.68 ± 0.46 b 4.79 ± 0.38 a
C18:1 t 9,t 11 -   0.37 ± 0.10 a 0.28 ± 0.09 a 0.06 ± 0.01 b 0.06 ± 0.02 b
∑ CLA 0.09 ± 0.01 d 0.35 ± 0.02 c 0.41 ± 0.04 c 2.83 ± 0.07 b 3.68 ± 0.15 a
VA + C18:2 c 9,t 11 0.09 ± 0.01 d 0.59 ± 0.04 c 0.71 ± 0.03 c 4.97 ± 0.25 b 6.50 ± 0.30 a
∑ BCFA 0.44 ± 0.12 d 1.59 ± 0.15 c 1.83 ± 0.13 b 1.97 ± 0.16 b 2.38 ± 0.14 a
  1. FA distribution of HT-29 cells after incubation with milk lipids (ML conventional and ML Alpine) given as FFA-mixtures in ethanol. Means (n = 6) of FAME [%] significantly differ without the same letter (a, b, c, d), two-way ANOVA Tukey post hoc test P < 0.05.